The targeting vector we used (Figure 1a ) destroys the junction between exon 13 and 14 -which forms the active site of the first catalytic domain (D1) of PTPα [4] -and disrupts the open reading frame of downstream exons. Two PTPα-targeted embryonic stem (ES) cell clones, both confirmed to have a single site of integration (data not shown), were used to produce chimeric mice that transmitted the modified PTPα allele to their offspring. PCR (data not shown) and Southern blot analyses of tail genomic DNA confirmed the transmission of the modified PTPα allele(s) (Figure 1b) . The PTPα +/-and PTPα -/-mice were viable, fertile and without any observable abnormalities up to 9 months of age. One line of mice was used for the experiments detailed below. Some of these experiments were also carried out with mice from the other line, with similar results (see Supplementary material published with this paper on the internet).
Figure 1
Targeted ablation of the PTPα gene. (a) A schematic representation of the PTPα wild-type allele (top), targeting vector (middle) and the modified allele (bottom). The targeting vector was made by replacing the SphI-KpnI fragment with a NEO cassette, and an HSV thymidine kinase (TK) gene was ligated to the 5′ end of the construct. P1 and P2 are primers used in the initial ES cell colony screening. Positive clones were later confirmed by Southern blotting of EcoRI-restricted genomic DNA using probe A. E, EcoRI; K, KpnI; N, NheI; S, SphI; E11-E18 are exon numbers. (b) NheI-digested genomic DNA from a PTPα-targeted ES cell clone that produced a germline chimera, and from tail biopsies from PTPα +/+ , PTPα +/-and PTPα -/-mice, was hybridized with probe B. Primers P3 and P4 were subsequently used to PCR-genotype the mice. (c) Brain lysates (40 µg) were analysed for PTPα expression by western blotting (top panel) and, as a loading control, for actin (bottom panel). Src activity is linked to its phosphorylation state, with dephosphorylation of Tyr527 resulting in elevated kinase activity [11, 12] . Phosphopeptide mapping of Src from 32 P-labeled PTPα +/+ and PTPα -/-fibroblasts showed a 31 kDa fragment corresponding to the serine/threoninephosphorylated amino terminus, and a 4 kDa carboxy-terminal phosphopeptide containing the regulatory Tyr527 site (Figure 3a) . The ratio of the 31 kDa to the 4 kDa phosphopeptide was 4.5 for PTPα -/-fibroblast Src, about fourfold lower than the ratio of 19 for PTPα +/+ fibroblast Src. Assuming that serine/threonine phosphorylation of the amino terminus of Src is not affected by PTPα, this indicates that the absence of PTPα results in higher phosphorylation of Tyr527.
An anti-Src antibody (Src2) that recognizes only the Tyr527-dephosphorylated form of Src [9] was used to confirm the above results. Brain lysates were precipitated with either this antibody or with Ab-1, which recognizes Src independent of its phosphorylation state (Figure 3b ). Whereas similar amounts of Src were precipitated by Ab-1 from brains of all genotypes, less Src was precipitated by the Src2 antibody from PTPα -/-and PTPα +/-brains (about 42% and 47%, respectively) than from PTPα +/+ brains (Figure 3c ).
Together with the phosphopeptide mapping, these results indicate that reduced activity of Src in the PTPα -/-mice is due to the absence of PTPα-mediated dephosphorylation of the regulatory carboxy-terminal Tyr527. that PTPα is a Src/Fyn phosphatase. Furthermore, these results demonstrate that PTPα is a positive physiological regulator of these Src family tyrosine kinases. The lack of gross phenotypic abnormalities of the mutant animals suggests that the catalytic function of PTPα is not essential for embryonic development, or perhaps reflects the potential expression and correct localization of truncated extracellular forms of PTPα which can fulfill an unknown normal function(s) as a ligand. Alternatively, this observation could reflect the reduced but residual Src/Fyn activities. Studies of Src-and Fyn-deficient mice indicate that Src is not required for general cell viability [13] and that Fyn is not required for general growth and differentiation [14] . Specialized and overlapping phenotypes of these mice or alterations in cells derived from them have since been described [15] , and further examination of the PTPα -/-mice will determine whether a lack of PTPα-activated Src or Fyn gives rise to similar, or to other specialized or restricted, differences which are not grossly apparent.
Alterations in phosphotyrosyl proteins

Materials and methods
Generation of PTPα-deficient mice
PTPα genomic clones were isolated from a 129Sv genomic DNA library in Lambda DASH II (a gift from P. Stambrook). The targeting vector was constructed from a 7 kb EcoRI fragment isolated from one of the clones, and had a neo gene flanked by 2 kb of 5′ homology and 4.5 kb of 3′ homology (Figure 1a ). An HSV thymidine kinase gene (a gift from L. Kranias) was cloned upstream of the 5′ homology region as a negative selection marker. ES cells (RW4, Genome Systems) were electroporated with the targeting vector and subjected to G418 and ganciclovir selection. Resistant colonies were analyzed by PCR using primers P1 and P2 and positive clones confirmed by Southern blotting using probe A (Figure 1a ) and the neo probe. The PTPα-targeted clones were injected into C57Bl/6 blastocysts to generate chimeric mice. Male germline chimeras were mated to Blk Swiss mice to produce mice heterozygous for the PTPα allele, and these were mated to generate mice lacking PTPα. Primary fibroblasts were prepared from day 14 embryos of matings of PTPα heterozygotes. Yolk sac or embryonic liver DNA was used for PCR genotyping.
Immunoprecipitation, western blotting and kinase assays
Whole brains or primary embryonic fibroblast cultures (passages 3 and 4) were lysed in modified RIPA buffer [3] . Immunoprecipitates were prepared from lysates (0.5-0.8 mg protein) using either anti-Src (Ab-1, Oncogene Science, or Src2, Santa Cruz), or anti-Fyn (FYN3-G, Santa Cruz) antibodies. Anti-PTPα-D1 antiserum 2205, anti-Src, anti-Fyn, anti-actin (Sigma A2066) or anti-phosphotyrosine PY20 (Transduction Laboratories) antibodies were used for immunoblotting. Src and Fyn immunoprecipitates were assayed for kinase activity, and Src phosphopeptide mapping was carried out essentially as described [1] .
Supplementary material
Supplementary figures showing the Csk and Src activities of PTPα mutant mice and additional methodological details are published with this paper on the internet.
Figure 4
Phosphotyrosyl protein profiles in wild-type and PTPα-deficient mice. The tyrosine kinase Csk is a key negative regulator of Src, phosphorylating Tyr527 to maintain Src in an inhibited state [S1,S2]. Although PTPα could indirectly activate Src by direct or indirect inhibition of Csk, no alterations in Csk protein levels were detected by immunoblotting of PTPα +/+ , PTPα +/-, and PTPα -/-brain lysates, and Csk immunoprecipitates showed no differences in in vitro kinase activity.
Supplementary materials and methods
The Csk immunoprecipitates (antibody C-20, Santa Cruz) were assayed in reactions containing 50 mM Tris pH 7.4, 3 mM MnCl 2 , 0.1 mM Na 3 VO 4 , 0.1 mM [γ-32 P]ATP and 1.4 mM RR-Src peptide (RRLIEDAEYAARG). After 30 min at 30°C, the Csk reactions were spotted onto P81 phosphocellulose papers which were washed and quantitated for radioactivity. The counts per minute (cpm) of reactions containing control immunoprecipitates prepared without anti-Csk antibody were taken as background and subtracted from those of reactions containing the Csk immunoprecipitates. As a positive control, recombinant Csk was also assayed and found to have excellent kinase activity towards this peptide substrate (data not shown).
